Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Sep;46(9):2555-61.
doi: 10.1161/STROKEAHA.115.009947. Epub 2015 Jul 30.

Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis

Kang-Ling Wang  1 , Gregory Y H Lip  1 , Shing-Jong Lin  1 , Chern-En Chiang  2
Affiliations
Meta-Analysis

Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis

Kang-Ling Wang et al. Stroke. 2015 Sep.

Abstract

Background and purpose: The use of vitamin K antagonists (VKAs), the cornerstone treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived risk of serious bleeding in Asia. Non-VKA oral anticoagulants (NOACs) are safer alternatives. Here, we evaluate performance differences of NOACs between Asians and non-Asians.

Methods: We compared efficacy and safety of NOACs between patients enrolled in Asian and non-Asian countries using aggregative data from phase III clinical trials. The odds ratios (ORs [95% confidence interval]) were calculated by a random effects model.

Results: Comparing with VKAs, standard-dose NOACs reduced stroke or systemic embolism (OR=0.65 [0.52-0.83] versus 0.85 [0.77-0.93], P interaction= 0.045) more in Asians than in non-Asians and were safer in Asians than in non-Asians about major bleeding (OR=0.57 [0.44-0.74] versus 0.89 [0.76-1.04], P interaction=0.004), hemorrhagic stroke (OR=0.32 [0.19-0.52] versus 0.56 [0.44-0.70], P interaction=0.046) in particular, whereas gastrointestinal bleeding was significantly increased in non-Asians (OR=0.79 [0.48-1.32] versus 1.44 [1.12-1.85], P interaction=0.041). Generally, low-dose NOACs were safer than VKAs without heterogeneity in efficacy and safety between Asians and non-Asians, except for ischemic stroke, major, and gastrointestinal bleeding.

Conclusions: Our findings suggest that standard-dose NOACs were more effective and safer in Asians than in non-Asians, whereas low-dose NOACs performed similarly in both populations.

Keywords: anticoagulants; atrial fibrillation; hemorrhage; stroke.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Efficacy outcomes of stroke or systemic embolism (A), ischemic stroke (B), myocardial infarction (C), and all-cause mortality (D) for the standard-dose non–vitamin K antagonist (VKA) oral anticoagulants (NOACs) vs VKAs. CI indicates confidence interval; and OR, odds ratio.
Figure 2.
Figure 2.
Safety outcomes of major bleeding (A), intracranial hemorrhage (B), hemorrhagic stroke (C), and gastrointestinal bleeding (D) for the standard-dose non–vitamin K antagonist (VKA) oral anticoagulants (NOACs) vs VKAs. CI indicates confidence interval; and OR, odds ratio.
Figure 3.
Figure 3.
Efficacy outcomes of stroke or systemic embolism (A), ischemic stroke (B), myocardial infarction (C), and all-cause mortality (D) for the low-dose non–vitamin K antagonist (VKA) oral anticoagulants (NOACs) vs VKAs. CI indicates confidence interval; and OR, odds ratio.
Figure 4.
Figure 4.
Safety outcomes of major bleeding (A), intracranial hemorrhage (B), hemorrhagic stroke (C), and gastrointestinal bleeding (D) for the low-dose non–vitamin K antagonist (VKA) oral anticoagulants (NOACs) vs VKAs. CI indicates confidence interval; and OR, odds ratio.
See this image and copyright information in PMC

References

    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867. - PubMed
    1. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309–315. doi: 10.1016/j.jacc.2007.01.098. - PubMed
    1. Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG RealiseAF investigators. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014;107:77–87. doi: 10.1016/j.acvd.2014.01.001. - PubMed
    1. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111:789–797. doi: 10.1160/TH13-11-0948. - PubMed
    1. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129:1568–1576. doi: 10.1161/CIRCULATIONAHA.113.005451. - PubMed

Publication types

MeSH terms